Desmoteplase as a potential treatment for cerebral ischaemia

Expert Opinion on Investigational Drugs

Volumn 23, Issue 6, 2014, Pages 865-873

  Patel, Rikesh ^a   Ispoglou, Sevasti ^a   Apostolakis, Stavros ^b  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Acute ischaemic stroke; Desmoteplase; Fibrin selectivity; Neurotoxicity; Plasminogen activator; Thrombolysis

Indexed keywords

ALTEPLASE; DESMOTEPLASE; FIBRIN; FIBRINOLYTIC AGENT; PLACEBO; PLASMINOGEN ACTIVATOR; SALIVARY PLASMINOGEN ACTIVATOR ALPHA 1, DESMODUS ROTUNDUS;

ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FIBRINOLYSIS; HUMAN; NEUROTOXICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; THROMBOSIS; ANIMAL; DRUG SCREENING; STROKE;

ANIMALS; BRAIN ISCHEMIA; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG EVALUATION, PRECLINICAL; FIBRINOLYTIC AGENTS; HUMANS; PLASMINOGEN ACTIVATORS; STROKE;

EID: 84900832644     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.911285     Document Type: Article

References (42)

1. CDC. Prevalence of stroke-United States, 2006-2010. MMWR Morb Mortal Wkly Rep 2012; 61(20): 379-82
2. Norrving B, Kissela B. The global burden of stroke and need for a continuum of care. Neurology 2013;80(3 Suppl 2):S5-12
3. Di Carlo A. Human and economic burden of stroke. Age Ageing 2009;38:4-5
4. Rickles FR. Thrombolytic (fibrinolytic) drugs and progress in treating cardiovascular disease. FASEB J 2005;19:671
5. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med 1995;333:1581-7
6. Jauch EC, Saver JL, Adams HP Jr, et al. American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870-947
7. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-703
8. Harraf F, Sharma AK, Brown MM, et al. A multicentre observational study of presentation and early assessment of acute stroke. BMJ 2002;325:17-21
9. Wardlaw JM, Sandercock PA, Murray V. Should more patients with acute ischaemic stroke receive thrombolytic treatment? BMJ 2009;339:b4584
10. Baird AE, Benfield A, Schlaug G, et al. Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol 1997;41:581-9
11. Karonen JO, Vanninen RL, Liu Y, et al. Combined diffusion and perfusion MRI with correlation to single-photon emission CT in acute ischemic stroke, ischemic penumbra predicts infarct growth. Stroke 1999;30:1583-90
12. Warach S. Thrombolysis in stroke beyond three hours: targeting patients with diffusion and perfusion MRI. Ann Neurol 2002;51:11-13
13. Butcher KS, Parsons M, MacGregor L, et al. Refining the perfusion-diffusion mismatch hypothesis. Stroke 2005;36:1153-9
14. Reddrop C, Moldrich RX, Beart PM, et al. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 2005;36:1241-6
15. Liberatore GT, Samson A, Bladin C, et al. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003;34:537-43
16. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005;129:307-21
17. Hawkey C. Plasminogen activator in saliva of the vampire bat Desmodus rotundus. Nature 1966;211:434-5
18. Medcalf RL. Desmoteplase: discovery, insights and opportunities for ischaemic stroke. Br J Pharmacol 2012;165:75-89
19. Krätzschmar J, Haendler B, Langer G, et al. The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: cloning and expression. Gene 1999;105:229-37
20. Schleuning WD. Vampire bat plasminogen activator DSPA-Alpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection. Haemostasis 2001;31:118-22
21. Tellgren-Roth A, Dittmar K, Massey SE, et al. Keeping the blood flowing-plasminogen activator genes and feeding behavior in vampire bats. Naturwissenschaften 2009;96:39-47
22. Renatus M, Stubbs MT, Huber R, et al. Catalytic domain structure of vampire bat plasminogen activator: a molecular paradigm for proteolysis without activation cleavage. Biochemistry 1997;36:13483-93
23. Seeds NW, Williams BL, Bickford PC. Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science 1995;270:1992-4
24. Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995;377:340-4
25. Tsirka SE, Rogove AD, Bugge TH, et al. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 1997;17:543-52
26. Tsirka S, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature 1996;384:123-4
27. Traynelis SF, Lipton SA. Is tissue plasminogen activator a threat to neurons? Nat Med 2001;7:17-18
28. Benchenane K, Berezowski V, Ali C, et al. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation 2005;111:2241-9
29. Benchenane K, Berezowski V, Ali C, et al. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation 2005;111(17):2241-9
30. Niego B, Freeman R, Puschmann TB, et al. tPA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. Blood 2012;119:4752-61
31. Adibhatla RM, Hatcher JF. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets 2008;7(3):243-53
32. Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010;38(3):376-85
33. Hildebrand M, Bhargava AS, Bringmann P, et al. Pharmacokinetics of the novel plasminogen activator Desmotus rotundus plasminogen activator and extrapolation to man. Fibrinolysis 1996;10:269-76
34. Sakharov DV, Barrertt-Bergshoeff M, Hekkenberg RT, Rijken DC. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro. Thromb Haemost 1999;81:605-12
35. Witt W, Maass B, Baldus B, et al. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. Circulation 1994;90:421-6
36. Witt W, Baldus B, Bringmann P, et al. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. Blood 1992;79:1213-17
37. Muschick P, Zeggert D, Donner P, Witt W. Thrombolytic properties of Desmodus (vampire bat) salivary plasminogen activator DSPAa1, alteplase and streptokinase following intravenous bolus injection in a rabbit model of carotid artery thrombosis. Fibrinolysis 1993;7:284-90
38. Hacke W, Albers G, Al-Rawi Y, DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73
39. Furlan AJ, Eyding D, Albers GW, DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37:1227-31
40. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009;8:141-50
41. Fiebach JB, Al-Rawi Y, Wintermark M, et al. Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase. Stroke 2012;43:1561-6
42. von Kummer R, Albers GW, Mori E; DIAS Steering Committees. The Desmoteplase in Acute Ischemic Stroke (DIAS) clinical trial program. Int J Stroke 2012;7:589-96